<DOC>
	<DOCNO>NCT02670668</DOCNO>
	<brief_summary>The study determine prevalence potential chemo-response relate gene mutation TNBC patient pCR SD/PD group , achieve NAC ; evaluate potential relationship gene mutation NAC-response TNBC patients.Based result , characterize TNBC phenotypical molecular perspective , order identify potential new target agent individualize treatment .</brief_summary>
	<brief_title>Mutation BRCA1/2 Other Potential Genes Triple-negative Breast Cancer</brief_title>
	<detailed_description>This single centre，exploratory，parallel retrospective study analysis mutation expression tBRCA1/2 potential gene triple-negative breast cancer . Patients receive neoadjuvant chemotherapy paclitaxel carboplation enrol study . The participant require clinical stage II III breast cancer clinical radiographically measurable residual tumor core biopsy . We enroll patient pCR SD/PD , achieve complete NAC . Every group enroll 50 patient . This study identify relationship different gene mutation expression , may target currently available investigational drug , chemo-response . Patients fulfil inclusion/exclusion criterion . We conduct retrospective chart review 100 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Patients receive neoadjuvant chemotherapy paclitaxel carboplation enrol study . ( 1 ) histologically confirm mainly invasive breast carcinoma ( 2 ) unilateral noninflammatory tumor ( 3 ) status ER , PR HER2 available negative ( 4 ) The participant require clinical stage II III breast cancer clinical radiographically measurable residual tumor core biopsy . ( 5 ) patient pathological evaluation NAC ( 6 ) pathologic tissue available immunohistochemistry next generation sequencing ( 1 ) carcinoma situ ( 2 ) receive less 4 cycle neoadjuvant chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>BRCA1/2 ; Mutations ; Neoadjuvant chemotherapy ; TNBC</keyword>
</DOC>